PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS

MLA

Efstathios Kastritis, et al. “Pb2122: A Phase 1/2 Multi-Center, Dose-Finding Study Investigating the Safety, Tolerability, Pk and Efficacy of Zn-D5, a Novel Bcl-2 Inhibitor, in Patients with Relapsed/Refractory Al Amyloidosis.” HemaSphere, vol. 7, Aug. 2023, p. e5544426. EBSCOhost, https://doi.org/10.1097/01.HS9.0000975252.55444.26.

APA

Efstathios Kastritis, Jeffrey Matous, Jesus Berdeja, Emad Abro, Bradley Augustson, Valentin Cabañas Perianes, M. Theresa Cibeira, Yael Cohen, Michael Fong, Moshe Gatt, Veronica Gonzalez DE LA Calle, Fiona Kwok, Noa Lavi, Hila Magen, Albert Oriol, Giovanni Palladini, Keith Stockerl-Goldstein, Taylor Eves, Cheng Zheng, & Anthony Fiorino. (2023). Pb2122: A Phase 1/2 Multi-Center, Dose-Finding Study Investigating the Safety, Tolerability, Pk and Efficacy of Zn-D5, a Novel Bcl-2 Inhibitor, in Patients with Relapsed/Refractory Al Amyloidosis. HemaSphere, 7, e5544426. https://doi.org/10.1097/01.HS9.0000975252.55444.26

Chicago

Efstathios Kastritis, Jeffrey Matous, Jesus Berdeja, Emad Abro, Bradley Augustson, Valentin Cabañas Perianes, M. Theresa Cibeira, et al. 2023. “Pb2122: A Phase 1/2 Multi-Center, Dose-Finding Study Investigating the Safety, Tolerability, Pk and Efficacy of Zn-D5, a Novel Bcl-2 Inhibitor, in Patients with Relapsed/Refractory Al Amyloidosis.” HemaSphere 7 (August): e5544426. doi:10.1097/01.HS9.0000975252.55444.26.